ORMP - Oramed Net earnings per share (EPS TTM)
The absence of debt and an excess of liquid assets allow Oramed Pharmaceuticals (ORMP) to invest consistently in R&D. The 12-month net income per share history confirms this financial foundation, where the parameter value equals 3.40. Business prospects rely on oral insulin delivery systems, although ultimate success depends on regulatory approval and patent protection.
Analytical breakdowns and data insights for company Oramed (ORMP)
- share price and expert price forecast:
- market capitalization statistics:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity Oramed Pharmaceuticals|ORMP - Long-Term Liabilities to Capital|Short-Term Debt to Equity Oramed Pharma|ORMP - Aggregate Debt Obligations|Debts to Book Capitalization Oramed Pharmaceuticals Inc.|ORMP - Company Long-Term Debts|Company Short-Term Debt Oramed Pharmaceuticals|Quick Ratio oramed.com
- net income and valuation multiples indicators:
ORMP - Company Net Income|Projected Future Earnings Oramed Pharmaceuticals|ORMP - Price to Earnings Multiple|Projected Price to Earnings Oramed Pharma|ORMP - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Oramed Pharmaceuticals Inc.|ORMP - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Oramed Pharmaceuticals|ORMP - Earnings per share for the trailing year|Quarterly EPS earnings growth oramed.com|ORMP - Earnings growth in current year|Net earnings per share growth forecast for next year Oramed Pharmaceuticals
- revenue and sales proceeds data:
General company analysis:oramed.com (ORMP)
Net income per share reflects the portion of equity in the company's total income. This metric is calculated by dividing the total annual profit by the total number of securities. Analyzing net income per share over the last four quarters allows for an assessment of operational efficiency trends. For Oramed Pharmaceuticals (ORMP), this growth depends on optimizing costs for the specialized distribution of insulin products. Controlling logistics expenses directly determines the final yield of each share.
Competitors of Oramed Pharmaceuticals (ORMP)
HLN: Net earnings per share for the last 12 months|kenvue.com - Earnings per share for the last four quarters|VRNA: Net earnings per share (EPS TTM)|Jyong Biotech Limited - Earnings per share for the trailing year|LGND (Ligand Pharma) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Amneal Corp AMRX|Earnings per share for the last twelve months Perrigo Company plc (PRGO)|ALVO (alvotech.com) - Earnings per share for the trailing year|Earnings per share for the last twelve months Liquidia LQDA|Galapagos N.V. (GLPG) - Net earnings per one share for the last twelve months|ANIP - Earnings per share for the last twelve months|Earnings per share for the trailing year MNKD (Afrezza)|AMPH: Net earnings per share (EPS TTM)|pacira.com (PCRX) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months ARS Pharmaceuticals, Inc.|Net earnings per share for the last 12 months Theravance Biopharma Inc (TBPH)|Net earnings per share (EPS TTM) AQST|SCPH - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) TECX (Tectonic Therapeutic)|TNXP: Earnings per share for the last 12 months|SXTC: Net earnings per share for the last 12 months|Earnings per share for the trailing year EPRX (Eupraxia Pharmaceuticals)|BioHarvest (BHST) - Earnings per share for the last twelve months|Earnings per one share for the last 12 months EXOZ (Invizyne)|ENTX (Entera Bio Ltd) - Net earnings per share (EPS TTM)|HYFT: Earnings per share for the trailing year|Net earnings per share (EPS TTM) ABVC|Net earnings per share (EPS TTM) Cumberland Pharmaceuticals Inc (CPIX)|Earnings per share for the last twelve months Quantum BioPharma Limited QNTM|Earnings per share for the trailing year FGEN|TELO - Earnings per share for the last twelve months|Rani Therapeutics (RANI) - Net earnings per share for the last 12 months|SNYR: Net earnings per share (EPS TTM)|Rallybio (RLYB) - Net earnings per share (EPS TTM)|LEXX (Lexaria Bioscience Corp) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Pulmatrix Corporation (PULM)|Net earnings per share (EPS TTM) PTHL|APM - Net earnings per one share for the last twelve months|Lyra Therapeutics - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Impact BioMedical, Inc. IBO|TNFA: Net earnings per share for the last 12 months|cbdMD, Inc. - Earnings per share for the last four quarters|PRFX: Net earnings per share (EPS TTM)|CYTO - Net earnings per share for the last four quarters|LIPO (Lipella Pharmaceuticals, Inc.) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months OptiNose Inc (OPTN)|Net earnings per share (EPS TTM) PIRS|Net earnings per share (EPS TTM) Procaps Group Corp (PROC)|Earnings per share for the last twelve months Petros Pharmaceuticals PTPI|qlsyy.net - Earnings per share for the last twelve months|SLRN - Earnings per share for the last twelve months|Net earnings per share for the last four quarters TFF Pharmaceuticals Inc. TFFP
